Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 654.85 INR
Change Today -10.25 / -1.54%
Volume 23.1K
ARTD On Other Exchanges
Symbol
Exchange
Natl India
As of 7:05 AM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

aarti drugs ltd (ARTD) Snapshot

Open
665.10
Previous Close
665.10
Day High
665.10
Day Low
652.00
52 Week High
04/8/15 - 874.90
52 Week Low
05/27/14 - 191.00
Market Cap
15.9B
Average Volume 10 Days
92.9K
EPS TTM
31.90
Shares Outstanding
24.2M
EX-Date
02/4/15
P/E TM
20.5x
Dividend
8.00
Dividend Yield
1.18%
Current Stock Chart for AARTI DRUGS LTD (ARTD)

Related News

No related news articles were found.

aarti drugs ltd (ARTD) Related Businessweek News

No Related Businessweek News Found

aarti drugs ltd (ARTD) Details

Aarti Drugs Limited is engaged in pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti inflammatory, cardioprotectant, antidiarrhoeals/antiprotozoles, antifungals, antiarthritis/osteoporosis, antihistamine, antibiotic, antidiabetic, alzheimer’s treatment, antihypertensive, antiBPH, sedative, vitamins, traquilizar, and antipsychotic. It also provides steroids, such as hydrocortisone sodium succinate sterile and hydrocortisone acetate; pharmaceutical intermediate products comprising valsartan, capecitabine, celecoxib, raloxifene, ketoconazole, and ziprasidone; and specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, methyl nicotinate, N-methyl methane sulphonamide, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, and para toluene sulphonyl chloride. In addition, the company’s products under development comprises Telmisartan for the treatment of cardiovascular diseases; Topiramate for anticonvulsant; Aripiprazole for the treatment of antipsychotic; Acamprosate for alcoholism treatment; Hydralazine HCl and Labetalol for the treatment of antihypertensive; Propafenone HCl for antiarrhythmic treatment; and Ticonazole for use as an antifungal. It also exports its products to 97 countries, as well as offers contract manufacturing services. Aarti Drugs Limited was founded in 1984 and is based in Mumbai, India.

Founded in 1984

aarti drugs ltd (ARTD) Top Compensated Officers

Chairman, Chief Executive Officer, Managing D...
Total Annual Compensation: 5.8M
Joint Managing Director, Executive Director, ...
Total Annual Compensation: 5.0M
Managing Director, Whole-Time Director, Membe...
Total Annual Compensation: 4.9M
Whole-Time Director, Member of Share Transfer...
Total Annual Compensation: 5.0M
Whole-Time Director
Total Annual Compensation: 484.1K
Compensation as of Fiscal Year 2014.

aarti drugs ltd (ARTD) Key Developments

Aarti Drugs Limited Recommends Final Dividend for the Fiscal 2015

Aarti Drugs Limited has announced that the board of directors of the company at its meeting held on May 20, 2015, has recommended final dividend of INR 3.00 per share for the fiscal 2015.

Aarti Drugs Limited Announces Audited Standalone Earnings Results for the Fourth Quarter and Year Ended March 31, 2015 and Consolidated Earnings Results for the Year Ended March 31, 2015

Aarti Drugs Limited announced audited standalone earnings results for the fourth quarter and year ended March 31, 2015 and consolidated earnings results for the year ended March 31, 2015. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 2,776.1 million against INR 2,817.9 million a year ago. Profit from operations before other income, finance costs & exceptional items was INR 348.2 million against INR 351.0 million a year ago. Profit from ordinary activities before tax was INR 250.6 million against INR 259.5 million a year ago. Net profit was INR 188.6 million or INR 7.79 per basic and diluted share before and after extraordinary items against INR 219.5 million or INR 9.07 per basic and diluted share before and after extraordinary items a year ago. For the year, on standalone basis, the company reported net sales/income from operations of INR 10,844.8 million against INR 9,699.4 million a year ago. Profit from operations before other income, finance costs & exceptional items was INR 1,382.9 million against INR 1,182.3 million a year ago. Profit from ordinary activities before tax was INR 1,000.6 million against INR 847.6 million a year ago. Net profit was INR 776.0 million or INR 32.04 per basic and diluted share before and after extraordinary items against INR 617.1 million or INR 25.48 per diluted share before and after extraordinary items a year ago. For the year, on consolidated basis, the company reported net sales/income from operations of INR 10,942.7 million, profit from operations before other income, finance costs & exceptional items of INR 1,380.0 million, profit from ordinary activities before tax of INR 997.2 million and net profit of INR 772.5 million or INR 31.90 per basic and diluted share before and after extraordinary items.

Aarti Drugs Limited, Board Meeting, May 20, 2015

Aarti Drugs Limited, Board Meeting, May 20, 2015. Agenda: To approve audited standalone earnings results for the fourth quarter and year ended March 31, 2015 and consolidated earnings results for the year ended March 31, 2015; and to approve final dividend.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARTD:IN 654.85 INR -10.25

ARTD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ARTD.
View Industry Companies
 

Industry Analysis

ARTD

Industry Average

Valuation ARTD Industry Range
Price/Earnings 20.4x
Price/Sales 1.4x
Price/Book 5.1x
Price/Cash Flow 14.5x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AARTI DRUGS LTD, please visit www.aartidrugs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.